Your session is about to expire
← Back to Search
Financial Incentives for Quitting Smoking (FIESTA II Trial)
N/A
Waitlist Available
Led By Joseph Ladapo, MD, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
age ≥ 18 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
FIESTA II Trial Summary
This trial is testing whether financial incentives can help smokers quit, by comparing three different approaches. They will also compare how well these approaches work in the short term and long term, and whether they are a good investment.
Who is the study for?
This trial is for adults over 18 who have smoked tobacco in the last month, are considering quitting smoking, and can consent in English or Spanish. They must have an active U.S. phone number and address. It's not for those using only smokeless tobacco, pregnant or breastfeeding individuals, people discharged to institutions like nursing homes, or anyone unable to consent.Check my eligibility
What is being tested?
The study tests if financial rewards can help hospitalized smokers quit. Participants will receive smoking cessation counseling (Quitline), pharmacotherapy (like nicotine patches), and cash incentives for quitting or using these therapies effectively.See study design
What are the potential side effects?
There may be no direct medical side effects from participating; however, common challenges when quitting smoking include nicotine withdrawal symptoms such as irritability, cravings, difficulty concentrating, increased appetite leading to weight gain.
FIESTA II Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
FIESTA II Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
Secondary outcome measures
Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
Quality of life as measured by PROMIS-29 Profile v2.0
Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
+1 moreFIESTA II Trial Design
3Treatment groups
Experimental Treatment
Group I: Outcome-Based IncentivesExperimental Treatment3 Interventions
Group II: Goal-Directed IncentivesExperimental Treatment3 Interventions
Group III: Enhanced Usual CareExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Smoking cessation counseling (Quitline)
2015
N/A
~190
Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
2015
N/A
~190
Find a Location
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,534 Previous Clinical Trials
10,266,338 Total Patients Enrolled
NYU Langone HealthOTHER
1,370 Previous Clinical Trials
839,746 Total Patients Enrolled
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
878,956 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am being discharged to a nursing home or long-term care facility.I am 18 years old or older.I am able to understand and agree to participate in the study.I can give my consent in English or Spanish.You only use smokeless tobacco products.You have smoked tobacco within the last month.I am considering quitting smoking.
Research Study Groups:
This trial has the following groups:- Group 1: Goal-Directed Incentives
- Group 2: Outcome-Based Incentives
- Group 3: Enhanced Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there still availability for participants in this research?
"This clinical trial is not currently recruiting patients, as evidenced by the data listed on clinicialtrials.gov from its original posting date of January 6th 2020 and most recent edit taking place a few days ago on May 1st 2022. Despite this, 163 other studies are still actively enrolling participants at present."
Answered by AI
Who else is applying?
What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
What site did they apply to?
David Geffen School of Medicine
NYU Langone Health
Recent research and studies
Share this study with friends
Copy Link
Messenger